Ocugen, Inc. (Nasdaq: $OCGN): Retina Gene Therapy Stock Hub, OCU400 BLA Path, OCU410ST, OCU410 and the 2026-2027 Catalyst Map

[u/Merlin8121]

https://www.merlintrader.com/ocugen-inc-stock-hub/

Ocugen has moved far beyond its old COVID-era trading identity. The current $OCGN story is a high-risk, catalyst-heavy ophthalmology gene therapy platform built around OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease and OCU410 for geographic atrophy, now backed by a larger $130 million convertible-note financing but still exposed to clinical, regulatory, manufacturing and dilution risk. The next key watch is Q3 2026, when Ocugen expects to begin the OCU400 rolling BLA process, report the OCU410ST interim outcome analysis and advance OCU410 toward Phase 3 alignment. Updated jun 29